UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dose Finding in Oncology Trials Guided by Ordinal Toxicity Grades Using Continuous Dose Levels

Entropy (Basel, Switzerland), 2024-08, Vol.26 (8), p.687

2024

Volltextzugriff (PDF)

A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials

Statistics in medicine, 2017-01, Vol.36 (2), p.280-290

2017

Volltextzugriff (PDF)

Evaluating the Association of Adverse Events and Patient-Reported Symptoms to Endocrine Therapy Tolerability

Journal of clinical oncology, 2022-02, Vol.40 (4), p.430-431

2022

Volltextzugriff (PDF)

Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials

Statistical science, 2010-05, Vol.25 (2), p.217-226

2010

Volltextzugriff (PDF)

Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control

Statistics in medicine, 2014-09, Vol.33 (22), p.3815-3829

2014

Volltextzugriff (PDF)

Escalation with overdose control using time to toxicity for cancer phase I clinical trials

PloS one, 2014-03, Vol.9 (3), p.e93070

2014

Volltextzugriff (PDF)

Comparison between continuous and discrete doses for model based designs in cancer dose finding

PloS one, 2019-01, Vol.14 (1), p.e0210139-e0210139

2019

Volltextzugriff (PDF)

Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial

The American heart journal, 2021-07, Vol.237, p.90-103

2021

Volltextzugriff (PDF)

Translation of Innovative Designs Into Phase I Trials

Journal of clinical oncology, 2007-11, Vol.25 (31), p.4982-4986

2007

Volltextzugriff (PDF)

Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35

Journal of clinical oncology, 2021-12, Vol.39 (34), p.3800-3812

2021

Volltextzugriff (PDF)

On the properties of the toxicity index and its statistical efficiency

Statistics in medicine, 2021-03, Vol.40 (6), p.1535-1552

2021

Volltextzugriff (PDF)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer

PloS one, 2021-06, Vol.16 (6), p.e0252665-e0252665

2021

Volltextzugriff (PDF)

A Bayesian adaptive design for cancer phase I trials using a flexible range of doses

Journal of biopharmaceutical statistics, 2018-05, Vol.28 (3), p.562-574

2018

Volltextzugriff (PDF)

Visualizing adverse events in clinical trials using correspondence analysis with R-package visae

BMC medical research methodology, 2021-11, Vol.21 (1), p.1-244, Article 244

2021

Volltextzugriff (PDF)

Applying the Toxicity Index to Patient-Reported Symptom Data: An Example Using the European Organization for Research and Treatment of Cancer Colorectal Cancer–Specific Quality of Life Questionnaire

Clinical therapeutics, 2021-07, Vol.43 (7), p.1245-1252

2021

Volltextzugriff (PDF)

Simulation study comparing analytical methods for single-item longitudinal patient-reported outcomes data

Quality of life research, 2023-03, Vol.32 (3), p.827-839

2023

Volltextzugriff (PDF)

miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer

Clinical cancer research, 2014-09, Vol.20 (17), p.4636-4646

2014

Volltextzugriff (PDF)

Health‐related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R‐04

Cancer, 2022-09, Vol.128 (17), p.3233-3242

2022

Volltextzugriff (PDF)

RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization

Endocrine-related cancer, 2014-04, Vol.21 (2), p.311-326

2014

Volltextzugriff (PDF)

Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial

Cancer prevention research (Philadelphia, Pa.), 2023-11, Vol.16 (11), p.631-639

2023

Volltextzugriff (PDF)

UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan

Clinical cancer research, 2005-02, Vol.11 (3), p.1226-1236

2005

Volltextzugriff (PDF)

Transferring Inpatient Rehabilitation Facility Cancer Patients Back to Acute Care (TRIPBAC)

PM & R, 2014-09, Vol.6 (9), p.808-813

2014

Volltextzugriff (PDF)

Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control

Statistics in medicine, 2005-07, Vol.24 (14), p.2183-2196

2005

Volltextzugriff (PDF)

Number of Patients per Cohort and Sample Size Considerations Using Dose Escalation with Overdose Control

Journal of Probability and Statistics, 2012-01, Vol.2012 (2012), p.542-557

2012

Volltextzugriff (PDF)

Escalation with Overdose Control is More Efficient and Safer than Accelerated Titration for Dose Finding

Entropy (Basel, Switzerland), 2015-08, Vol.17 (8), p.5288-5303

2015

Volltextzugriff (PDF)

1 – 25 von 171

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(152)
Mit Volltextzugriff
(150)

Publikationsform

Sprache

Englisch
(171)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dose Finding in Oncology Trials Guided by Ordinal Toxicity Grades Using Continuous Dose Levels

A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials

Evaluating the Association of Adverse Events and Patient-Reported Symptoms to Endocrine Therapy Tolerability

Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials

Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control

Escalation with overdose control using time to toxicity for cancer phase I clinical trials

Comparison between continuous and discrete doses for model based designs in cancer dose finding

Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial

Translation of Innovative Designs Into Phase I Trials

Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35

On the properties of the toxicity index and its statistical efficiency

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer

A Bayesian adaptive design for cancer phase I trials using a flexible range of doses

Visualizing adverse events in clinical trials using correspondence analysis with R-package visae

Applying the Toxicity Index to Patient-Reported Symptom Data: An Example Using the European Organization for Research and Treatment of Cancer Colorectal Cancer–Specific Quality of Life Questionnaire

Simulation study comparing analytical methods for single-item longitudinal patient-reported outcomes data

miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer

Health‐related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R‐04

RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization

Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial

UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan

Transferring Inpatient Rehabilitation Facility Cancer Patients Back to Acute Care (TRIPBAC)

Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control

Number of Patients per Cohort and Sample Size Considerations Using Dose Escalation with Overdose Control

Escalation with Overdose Control is More Efficient and Safer than Accelerated Titration for Dose Finding

Suchergebnisse filtern